Literature DB >> 15938032

Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension.

Roberto Pontremoli1, Giovanna Leoncini, Francesca Viazzi, Denise Parodi, Valentina Vaccaro, Valeria Falqui, Angelica Parodi, Simone Vettoretti, Elena Ratto, Giacomo Deferrari.   

Abstract

Accurate cardiovascular risk evaluation is a prerequisite for devising cost-effective therapeutic strategies in patients with essential hypertension. In fact, the knowledge of concomitant risk factors, diabetes, target organ damage, or associated clinical conditions may be useful when deciding both treatment and BP goals. Thorough evaluation of target organ damage is the key to sensitive assessment of global risk, but cost-effective allocation of economic resources should also be taken into consideration. Thanks to its low cost and widespread availability, the search for microalbuminuria is a first-line tool for identifying hypertensive patients who are at higher cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15938032     DOI: 10.1681/asn.2004110955

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  3 in total

1.  Drugs and the kidney: more than a question of dose.

Authors:  Derek G Waller
Journal:  Br J Clin Pharmacol       Date:  2007-12       Impact factor: 4.335

Review 2.  Microalbuminuria in primary hypertension: a guide to optimal patient management?

Authors:  Francesca Viazzi; Francesca Cappadona; Roberto Pontremoli
Journal:  J Nephrol       Date:  2016-07-14       Impact factor: 3.902

3.  Associations between proteinuria and cardiovascular risk factors among hypertensive patients in Andkhoy, Afghanistan.

Authors:  Mohammad Shoaib Hamrah; Mohammad Hashem Hamrah; Hideki Ishii; Susumu Suzuki; Mohammad Hussain Hamrah; Mohammad Hassan Hamrah; Maimaiti Yisireyili; Naoaki Kano; Kyosuke Takeshita; Junichi Sakamoto; Toyoaki Murohara
Journal:  Nagoya J Med Sci       Date:  2016-12       Impact factor: 1.131

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.